131 related articles for article (PubMed ID: 21178509)
1. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
[TBL] [Abstract][Full Text] [Related]
2. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
3. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
4. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
[TBL] [Abstract][Full Text] [Related]
7. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
9. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
10. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
12. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
15. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
16. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
17. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
[TBL] [Abstract][Full Text] [Related]
20. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]